Related Experiment Video
Updated: Jul 16, 2025

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
Published on: December 5, 2017
Natural Allies for Heart Health: Nrf2 Activation and Cardiovascular Disease Management
Safir Ullah Khan1, Shahid Ullah Khan2, Muhammad Suleman3
1Hefei National Laboratory for Physical Sciences at the Microscale, School of Life Sciences, University of Science and Technology of China, Hefei, China.
Insights
Cardiovascular diseases (CVD) are linked to oxidative stress. Targeting the Nrf2 pathway with natural products shows promise for developing new cardioprotective treatments against CVD.
Area of Science:
- Cardiology
- Biochemistry
- Pharmacology
Background:
- Cardiovascular diseases (CVD) represent a major global health challenge, contributing significantly to mortality and morbidity.
- Oxidative stress (OS) is a key pathological mechanism underlying the development and progression of various CVDs.
- Current therapeutic strategies for CVDs face limitations, necessitating novel approaches.
Purpose of the Study:
- To explore the role of oxidative stress in cardiovascular diseases.
- To investigate the potential of nuclear erythroid 2-related factor 2 (Nrf2) as a therapeutic target for CVDs.
- To examine the cardioprotective effects of natural substances that activate Nrf2 signaling.
Main Methods:
- Review of existing literature on oxidative stress and cardiovascular diseases.
- Analysis of the function of Nrf2 in endogenous antioxidant defense systems.
- Exploration of natural products as Nrf2 activators for cardioprotection.
Main Results:
- Oxidative stress significantly contributes to cardiovascular dysfunction.
- Nrf2 is a critical regulator of cellular defense against oxidative stress.
- Natural compounds activating Nrf2 signaling demonstrate potential for mitigating CVD pathology.
Conclusions:
- Targeting Nrf2 represents a promising therapeutic strategy for managing cardiovascular diseases.
- Natural products offer a novel avenue for CVD treatment by activating Nrf2-mediated antioxidant pathways.
- Further research into Nrf2-activating natural substances could lead to advanced cardioprotective therapies.
Abstract:
The term "cardiovascular diseases" (CVD) refers to various ailments that affect the heart and blood vessels, including myocardial ischemia, congenital heart defects, heart failure, rheumatic heart disease, hypertension, peripheral artery disease, atherosclerosis, and cardiomyopathies. Despite significant breakthroughs in preventative measures and treatment choices, CVDs significantly contribute to morbidity and mortality, imposing a considerable financial burden. Oxidative stress (OS) is a fundamental contributor to the development and progression of CVDs, resulting from an inherent disparity in generating reactive oxygen species. The disparity above significantly contributes to the aberrant operation of the cardiovascular system. To tackle this issue, therapeutic intervention primarily emphasizes the nuclear erythroid 2-related factor 2 (Nrf2), a transcription factor crucial in regulating endogenous antioxidant defense systems against OS. The Nrf2 exhibits potential as a promising target for effectively managing CVDs. Significantly, an emerging field of study is around the utilization of natural substances to stimulate the activation of Nrf2, hence facilitating the promotion of cardioprotection. This technique introduces a new pathway for treating CVD. The substances above elicit their advantageous effects by mitigating the impact of OS via initiating Nrf2 signaling. The primary objective of our study is to provide significant insights that can contribute to advancing treatment methods, including natural products. These strategies aim to tackle the obstacles associated with CVDs.
Related Concept Videos
Rheumatic Heart Disease IV: Nursing Management
Rheumatic Heart Disease III: Medical Management
Heart Failure V: Medical Management
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Atherosclerosis III: Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

